Animal Vaccine Market was worth of USD 11.13 billion in 2021 and it is expected to reach 20.48 billion by the end of 2028 with the CAGR of 9.1% during Forecast Period.
Global Animal Vaccine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis To 2021-2027,Growing adoption of pets, increasing prevalence of zoonotic disease and food borne, rapid increasing demand in animal protein in human food are anticipated the growth in the global animal vaccine market. Additionally, technological advancement in developing animal health vaccine will fuel the market.
Animal vaccines plays an important role to prevent various disease among animals and it also helps them to fight against several diseases including zoonotic diseases. This vaccination is carried out by the veterinary medicines. Animal vaccination helps to protect pets, cattle and other animals from bacterial and viral disease. Vaccination stimulates the immune response without causing the disease itself in animal. Animal vaccination is found to be the most sustainable method & cost effective for controlling infectious disease. The production of animal pathogens and humans are always linked as at least 61% of all human pathogens originate from animals only. Animal health is vital and also contributes to companion animal & food production, keeping safe to animal owners, and prosperity in farming as well. Healthy animals help in keeping environment safe thus reducing zoonotic disease. The first animal vaccine was created by Louis Pasteur for chicken cholera in the year 1879. Louis also invented the Anthrax vaccine for cattle and sheep in 1881 including rabies vaccine in 1884.
COVID-19 pandemic has shown the negative impact on the global animal vaccine market, due to less availability of vaccine manufacturing unit including fewer workers. The risk of animal spreading corona virus is low as compared to the humans but still there were no such confirmed cases. The government restricted the transportation and allowing humans to go outside for preventing spreading of virus, which indirectly hampered the veterinary activities too. According to the worldometer, the confirmed cases of corona virus are 263,758,247 and death confirmed were 5,242,146 till 2nd Dec’ 2021.
Global Animal Vaccine market is segmented on the basis of products, animal type, route of administration, region and country level. Based on the products the global Animal Vaccine market is classified into inactivated vaccines, toxoid vaccines, DNA vaccine, subunit vaccine, attenuated vaccine, recombinant vaccine, and other. Based on the animal type the global animal vaccine market is classified into Livestock animal, companion animal and other. Based on the route of administration the global animal vaccine market is classified into oral vaccine, injection vaccine, spray vaccine and others.
By Animal Type
By Route of Administration
Some major key players for global animal vaccine market report cover prominent players like
January 28th, 2020: Automazioni VX Inc. and MSD Animal Health, a division of Kenilworth & Merck has introduced the Innoject Pro, newly designed subcutaneous chick vaccination technology. Innoject Pro provides increased accuracy of injection and greater stability during the vaccination process, reducing stress to chicks and improving operator safety. This IPPE was held in Atlanta, in the year 2020. The technology will be utilized in combination with MSD Innovax range of vaccines which provide long term protection to the infectious disease in poultry. Innoject Pro also features unique disinfection system that sprays disinfectant on the injection needles which helps to improve biosecurity and reduce contamination.
Growing adoption of pets, increasing prevalence of zoonotic and food borne disease, rapid increasing demand of animal protein in human food are anticipated the growth in the global animal vaccine market. Additionally, technological advancement in the development of animal vaccine will fuel the market.
Major factor that drives the growth of global animal vaccine market is increasing prevalence of zoonotic disease and rising adoption of pets. Increased adoption of pets like dogs, cats and ferrets will always create the demand for animal protection from various diseases. Vaccinating animals indirectly improve the world health and can help in reducing the polio in humans, animals, cattle’s, canine distemper and rabies in human and animals. The animal diseases vary and can include malnutrition, infertility, cancers, stress, hereditary and congenital defects, and, perhaps the most important, infections and parasitism due to micro-organisms which are also called as pathogen. Vaccine and antisera are mostly used for preventing diseases caused by pathogen and can also use to control organism like parasitic worm and fungi. According to the CDC, it is found those 4,951 cases of rabies in animals and 3 cases in humans in United States in the year 2018. Also, in wild animals accounted for 92% of cases of rabies were confirmed.
Furthermore, technological advancement in vaccine development also expected to support the market growth. The success of attenuated and live vaccine has enhanced the food security, attenuated the morbidity, livestock productivity, and mortality of several animal, human, and zoonotic diseases these are traditional vaccine technologies. However, the third-generation animal vaccine includes RNA, DNA, and recombinant viral vectors vaccine for cellular & humoral immune response, is economically manufactured, safe to use, and can be utilized to differentiate infected animals from vaccinated animals. Also, there are several attempts to develop effective vaccine against large number of diseases using recombinant DNA technology is still in progress on global level. Already in use are vaccine products from rDNA techniques to prevent diarrhea in newborn swine. According to the OECD, almost vaccines are estimated to 541 million USD, including to the 118 USD million for rabies vaccines, 109 USD million for cattle vaccine and 118 USD million for poultry products.
The restraining factor that will hamper the market is government regulation followed by the high storage cost of vaccines. Also, improper storage facility and delay in shipping of the vaccine can reduce the quality and immune response. Increasing partnership and collaboration between key players for the development of new vaccines and innovation of cost-effective vaccine are expected to create ample opportunities in the animal vaccine market.
This is due to the rising incidence of canine concerns and increasing prevalence of rabies and pets’ adoption is fueling the market growth in this region. Also, presence of major pharmaceutical company will compete to grow more in commercialization of animal vaccines. According to the Insurance Information Institute, the total number of animals insured in the year 2020 is 3.1 million. According to the Insurance research councils, nearly 30% of Americans has adopted a pet. For instance, according to the national pet owner’s survey, almost 85 million families own a pet.
Asia Pacific is projected to witness the highest growth in the global animal vaccine market due to the large population of livestock in the region. The prevention of such large number of livestock is the major concern for development of vaccine in this region. Vaccination is the most preferred method to keep animals safe which in turn will contribute to human health and safe environment. According to the FAO, the China is leading in the meat production for around 70.88% in year 2020, followed by Australia 4.01%. These cattle are also used in the farms, as meat and dairy products as well. According to the National Dairy Development Board, around 192.5 million cattle are there in India. According to the Frontiers Media S.A, meat consumption in this region is 125 million tons and that of milk consumption is 220 million tons.
The regions covered in this global animal vaccines market report is North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, Southeast Asia, Middle East, GCC (UAE, Saudi Arabia, Kuwait) Africa, etc.
Middle East and Africa
|Historical data||2018 - 2021|
|Forecast Period||2022 - 2028|
|Market Size in 2021:||USD 11.13 Billion|
|Base year considered||2021|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 20.48 Billion|
|Tables, Charts & Figures:||175|
|Animal Vaccine Companies||Zoetis, Elanco, Ceva, Virbac SA, Indian Immunologicals Ltd., Intas Pharmaceuticals Ltd, Ourofino Saúde Animal, Neogen Corporation, Merck & Co., Inc., Boehringer Ingelheim GmbH, Biogénesis Bagó, Phibro Animal Health Corporation, Romvac, Sanofi, and others.|
|Segments Covered||By Products, By Animal Type|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|